Pep IQ
← Pep IQ
Substantial preclinical foundation. Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) — the ACTH(4-7) neurotrophic fragment fused with a stabilising C-terminal Pro-Gly-Pro tail to resist enzymatic degradation. Mechanism: BDNF upregulation in hippocampus and cortex (1.4-fold protein, 3-fold mRNA after single 50 mcg/kg intranasal dose in rats; concurrent 1.6-fold TrkB phosphorylation), monoamine modulation (serotonin elevation specifically), neuroprotection via anti-apoptotic pathways. Romanova et al. 2006 demonstrated 6 daily intranasal Semax doses reduced cortical infarction volume after photoinduced ischaemia in rats with preserved memory function. Multiple cerebral ischaemia and Alzheimer's mouse-model studies show neuroprotective and anti-amyloid effects.
Two distinct frameworks. Russian clinical use: 0.1% solution for cognitive support and mild neuroprotection (400–900 mcg/day, split 2–3× daily, 5–14 day courses); 1% solution for stroke recovery (6,000–20,000 mcg/day depending on severity, 4–6 daily administrations, up to 10 days). Community nootropic use outside Russia: typically 400–900 mcg/day intranasal, 5 days on / 2 off, in 2–4 week cycles before longer break; SubQ alternative at 1 mg 2–3× weekly. Some users prefer the modified N-Acetyl Semax Amidate (Nasemax) for claimed superior potency. Cycling addresses modest tachyphylaxis seen with continuous use.
Substantial Russian clinical evidence base. Largest published stroke trial — Gusev et al. 2017 — 110 patients, 6,000 mcg/day for two 10-day courses with 20-day interval, showed elevated plasma BDNF and faster recovery on Barthel-index functional scoring. Multiple Russian acute ischaemic stroke trials. Lebedeva et al. 2018 — fMRI pilot in healthy subjects examining Default Mode Network changes. 30-day glaucoma trial. Small ALS/motor-neuron-disease study (27 patients) — Semax did not affect disease but improved mood and cognition. Cognitive Vitality (Alzheimer's Discovery Foundation) review notes that 'published literature of well-conducted studies is lacking' — the Russian trial methodology generally falls below FDA/EMA standards. No FDA-registered or EMA-registered Phase 2/3 trials exist.
Approved as a prescription drug in Russia and Ukraine — listed on Russia's official register of vital medications since 2011. Manufactured by JSC Peptogen as 0.1% and 1% intranasal formulations. Indications include ischaemic stroke, transient ischaemic attack, encephalopathy, optic nerve atrophy, and cognitive disorders including dementia. Not FDA-approved or EMA-approved; no regulatory applications currently pending in Western markets. Generally well-tolerated — main side effects are nasal irritation, mucosa discoloration, occasional glucose elevations in diabetics. WADA does not list Semax specifically.
Semax has one of the more substantial Russian clinical evidence bases on the platform — multiple decades of clinical use, regulatory approval in Russia/Ukraine, the 110-patient Gusev stroke trial, and a coherent BDNF-mediated mechanism. The evidence framework is Russian rather than Western, with less rigorous trial methodology and the Cognitive Vitality review explicitly noting the lack of well-conducted studies by Western standards. Standard nootropic protocol: 400–900 mcg/day intranasal, 5–14 day cycles. Russian clinical experience is most extensive in cognitive support and post-stroke recovery contexts; large-scale Western RCTs have not been conducted.
Semax was developed in Russia at the Institute of Molecular Genetics through a process of deliberate rational peptide design — taking adrenocorticotropic hormone (ACTH), identifying the fragment responsible for its CNS activity, and re-engineering it to remove the hormonal side effects while preserving and enhancing the neurological ones.
The core is the ACTH(4–7) fragment — Met-Glu-His-Phe — which carries the melanocortin-related brain activity. Researchers added a Pro-Gly-Pro (PGP) tripeptide at the C-terminus, initially to improve metabolic stability. It turned out PGP is not a passive tail — studies show it independently activates neurotrophin transcription in ischaemic brain tissue. Every amino acid in Semax is doing work.
The result was registered in Russia in 1996 for stroke recovery, optic nerve atrophy, and cognitive impairment. It's been available as a nasal spray in Russia and Ukraine ever since. Three decades of mostly Russian-language published research followed, with international interest accelerating in the 2020s as transcriptomic tools made its multi-pathway effects easier to characterise.
Semax's mechanism reads like a list of four separate drugs. The evidence behind each pathway varies in quality, but the breadth is unusual and has been confirmed across multiple research groups using transcriptomic and proteomic tools.
The "too many mechanisms" problem: Semax's broad mechanistic profile is both its strength and its credibility challenge. When a compound claims effects on BDNF, 1,500 genes, dopamine, serotonin, enkephalins, calcium dynamics, and spinal cord repair — it's natural to be sceptical. The honest answer is that the breadth is supported by data from multiple research groups and modern transcriptomic tools. But the clinical translation of preclinical gene expression data is notoriously difficult to predict, and Semax has not been through rigorous independent Western clinical trials.